---
title: "Assertio Holdings, Inc. (ASRT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ASRT.US.md"
symbol: "ASRT.US"
name: "Assertio Holdings, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T05:59:06.163Z"
locales:
  - [en](https://longbridge.com/en/quote/ASRT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ASRT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ASRT.US.md)
---

# Assertio Holdings, Inc. (ASRT.US)

## Company Overview

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.assertiotx.com](https://www.assertiotx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: D (0.71)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 142 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -14.15% |  |
| Net Profit YoY | -16.59% |  |
| P/B Ratio | 2.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 151115319.01 |  |
| Revenue | 102158000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -38.76% | E |
| Profit Margin | -34.94% | E |
| Gross Margin | 72.71% | A |
| Revenue YoY | -14.15% | E |
| Net Profit YoY | -16.59% | D |
| Total Assets YoY | -26.23% | E |
| Net Assets YoY | -30.31% | E |
| Cash Flow Margin | 19.84% | D |
| OCF YoY | -14.15% | E |
| Turnover | 0.41 | C |
| Gearing Ratio | 64.21% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Assertio Holdings, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-14.15%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-16.59%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "151115319.01",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "102158000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-38.76%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-34.94%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "72.71%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-14.15%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-16.59%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-26.23%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-30.31%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "19.84%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-14.15%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.41",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "64.21%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.23 | 155/190 | - | - | - |
| PB | 2.00 | 90/190 | 0.93 | 0.72 | 0.61 |
| PS (TTM) | 1.48 | 42/190 | 0.74 | 0.57 | 0.53 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 25% |
| Hold | 3 | 75% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 23.41 |
| Highest Target | 28.00 |
| Lowest Target | 18.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ASRT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ASRT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ASRT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ASRT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**